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Abstract 
 
Baraitser-Winter Cerebrofrontofacial syndrome (BWCFF) [BRWS; MIM #243310, 
614583] is a rare developmental disorder affecting multiple organ systems. It is 
characterised by intellectual disability (mild to severe) and distinctive facial 
appearance (metopic ridging/trigonocephaly, bilateral ptosis, hypertelorism). The 
additional presence of cortical malformations (pachygyria/lissencephaly) and ocular 
colobomata are also suggestive of this syndrome. Other features include moderate 
short stature, contractures, congenital cardiac disease and genitourinary 
malformations. BWCFF is caused by missense mutations in the cytoplasmic beta- 
and gamma-actin genes ACTB and ACTG1. We provide an overview of the clinical 
characteristics (including some novel findings in four recently diagnosed patients), 
diagnosis, management, mutation spectrum and genetic counselling.  
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Introduction 
 
The Baraitser-Winter syndrome [BRWS; MIM #243310, 614583] was first described in 
19881. It is a rare, autosomal dominant, developmental disorder. The main features 
include a distinctive facial appearance (metopic ridging/trigonocephaly, bilateral 
ptosis, hypertelorism), intellectual disability and structural brain abnormalities, 
predominantly pachygyria. Causative missense mutations in the ACTB [MIM 
102630] and ACTG1 [MIM 102560] genes were identified in 20122. Two other 
disorders, Fryns-Aftimos syndrome [MIM #243310]3 and Cerebrofrontofacial 
syndromes types 1 and 3 [MIM #243310]4 were previously thought to be separate 
clinical entities. It has now been demonstrated that they are also caused by ACTB & 
ACTG1 mutations, and Baraitser-Winter Cerebrofrontofacial syndrome (BWCFF) has 
been put forward as a unifying name5. More recently, fetal cases with 
microlissencephaly have been described, further extending the phenotypic 
spectrum6. Here we report the first instance of parent-child transmission, review the 
phenotypic and molecular characteristics of the approximately sixty cases published 
to date, illustrating key points with two additional patients. We discuss diagnosis, 
management, mutation spectrum and genetic counselling.  
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Clinical overview 
 
Craniofacial characteristics 
 
Individuals with BWCFF have a characteristic craniofacial appearance (Table 1), but 
there is a wide spectrum in severity. Hypertelorism, which may be significant7, and 
congenital non-myopathic ptosis is present in almost all cases. The eyebrows are 
often arched, which can increase with age. This may be partly due to an effort to 
raise the eyelids, although it is also seen in the absence of ptosis. The palpebral 
fissures are usually long and may be downslanting7-8. Epicanthic folds can be 
present1,9. Partial absence of the upper eyelashes has been reported8,10.  
 
Trigonocephaly or metopic ridging, associated with premature closure of the 
metopic suture, is common. A recently diagnosed female with a novel mutation had 
sagittal craniosynostosis, not previously reported, which required surgical correction 
(Fig. 1a, Patient 2). There is a round, flattened appearance to the face in infants. A 
progressive coarsening of facial features develops with age. The nose is usually short 
with a broad nasal bridge, anteverted nares and depressed nasal tip. A long 
philtrum, thin vermillion border and macrostomia are common5. Micro- or 
retrognathia may be present6,10. The palate is usually high arched.  Cleft lip and 
palate are seen in some patients. The ears are often posteriorly rotated, small and 
dysplastic5.  
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Ocular features 
 
Uni – or bilateral colobomata are present in about one third of patients, affecting the 
iris or retina2,5-6. Eyelid colobomata have been reported8. Microphthalmia is seen, but 
is uncommon5,9. There have been some reports of cataracts, myopia and 
strabismus8,11-12. A recently diagnosed male with a novel mutation presented with a 
unilateral congenital glaucoma, not previously reported in BWCFF (Fig. 1b, Patient 
4). 
 
Hearing  
 
Hearing loss is present in some cases, usually sensorineural, and can be 
progressive2,11,13.  
 
Growth and musculoskeletal manifestations 
 
Mild to moderate short stature in adulthood is common2,5. The neck is often short 
and may be webbed. Pterygia may affect one or more of the axillae, elbows and 
popliteal regions7-8. Pectus deformities are common and the nipples are often wide 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
spaced, hypoplastic and may be inverted. The shoulder muscle bulk may be reduced 
to a variable extent. Many patients develop an unusual posture with anteverted 
shoulders, flexed elbows and knees5. Camptodactyly and clinodactyly are rarer 
features3,10-11. The hallux may be broad and, uncommonly, duplex5,7. Talipes 
equinovarus is seen infrequently5.   
 
Neurology 
 
Cortical brain malformations have been reported in 60-70% of patients, and are most 
consistently seen in those with an ACTG1 mutation5. Pachygyria, frontal or 
perisylvian, is most common (Fig. 2)5-6 (personal observation). Lissencephaly with 
diffuse agyria has also been reported6,9. A few have periventricular nodules.  The 
corpus callosum often appears short and thick or may be hypoplastic or absent. 
Prominent perivascular spaces are common (Fig. 2a & b). Infratentorial structures 
are usually normal5. However, recently a fetus with an ACTG1 mutation, 
microlissencephaly and underdeveloped brain stem and cerebellum has been 
reported6. 
 
Microcephaly can be a feature. This is mostly mild with postnatal onset. However, 
Poirier et al6 reported two fetal cases with ACTG1 mutations and severe 
microcephaly, associated with lissencephaly/agyria. They described a third patient 
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with features of BWCFF, who presented with microcephaly and perisylvian 
pachygyria, who also had an ACTG1 mutation. The case of diffuse agyria previously 
described by Ramer et al9 with an ACTB mutation2, also had significant 
microcephaly.  
 
Developmental delay and learning difficulties are present in the vast majority of 
patients. Mild to moderate developmental delay may be found to a variable extent in 
those with no structural brain anomalies. Pachygyria and other structural cerebral 
changes are associated with mild to profound intellectual disability (ID), usually in 
keeping with the severity of the cortical malformation2,5,7.  
 
Epilepsy has so far only been seen in association with a structural brain anomaly and 
age of onset is very variable. The seizure disorder may be refractory to treatment. 
Other neurological features include generalised hypotonia or spasticity of the lower 
limbs2,5,7. 
 
Gearing et al.14 reported monozygotic twins with severe, progressive dystonia from 
the age of twelve years, with a unique p.Arg183Trp ACTB mutation. This has not 
been found in any other cases, and it remains to be seen whether this is a feature 
specific to this family.  
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Cardiovascular 
 
Congenital cardiac disease is a feature in around one third of patients. A patent 
ductus arteriosus is the most frequent finding. Ventricular or atrial septal defects 
have been reported7,10,13 and rarely bicuspid aortic valve and aortic stenosis9, mitral 
valve regurgitation5 and tricuspid regurgitation10. 
 
Genitourinary 
 
Genitourinary tract abnormalities include hydronephrosis, which is mostly 
bilateral5,10. Ectopic kidneys may also be a feature5. Renal duplication is found more 
rarely10,13. Undescended testes have been reported9,13.  
 
Gastrointestinal  
 
Umbilical hernias are relatively common, inguinal hernias less so8,13. Achalasia and 
bulbar palsy requiring gastrostomies were present in the twins reported by Gearing 
et al14. However as previously noted, these features may be unique to this family.  
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Antenatal 
 
Pregnancy is usually uneventful with normal growth. Two cases had hydrops fetalis 
with marked polyhydramnios7. Of note, these patients also had a more severe 
craniofacial phenotype.  
 
Malignancy  
 
Only two previously reported BWCFF patients have presented with haematological 
malignancies2,5. One of them, with an ACTB mutation, developed a precursor B-cell 
acute lymphatic leukaemia (ALL) at the age of eight years. The other, with an 
ACTG1 mutation, developed a cutaneous lymphoma at the age of nineteen years.  
 
Mutation spectrum & genotype-phenotype correlation 
 
Baraitser-Winter Cerebrofrontofacial syndrome is caused by heterozygous missense 
mutations in ACTB (Chr 7p22.1) and ACTG1 (Chr 17q25.3), which demonstrate 
clustering (Fig. 3) suggesting gain-of-function, but a dominant negative effect is also 
a possible mechanism2,15. This is supported by the observation that no similar 
phenotype has been found with deletions or duplications of these genes2. ACTB 
mutations predominate so far. It is notable that amino acid 196 is most often affected, 
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with sixteen recurrent cases thus far (p.Arg196His, p.Arg196Cys) 5, (and unpublished 
data). There is clinical heterogeneity amongst this group, even in those with the 
same mutation, suggesting the involvement of modifier genes5.  
 
ACTB and ACTG1 have a highly similar structure16, and it could therefore be 
surmised that mutations in either would have similar phenotypic effects. However, a 
single case with an ACTG1 mutation (p.Thr120Ile) demonstrated a milder 
craniofacial phenotype than several with an analogous ACTB variant2,7. Therefore, it 
has been suggested that ACTB mutations result in a more severe phenotype2,7. Our 
observations indicate that a severe craniofacial phenotype has so far been associated 
with ACTB variants, whereas ACTG1 mutation carriers are more likely, although not 
consistently17, to have a cortical brain malformation, hence also more severe 
intellectual disability and/or epilepsy. Indeed, the two fetuses described by Poirier et 
al.6 with microlissencephaly and facial features of BWCFF had novel mutations in 
ACTG1 (p.Ile75Leu & p.Pro343Ile). However, it should be noted that parental studies 
could not be undertaken in these cases, and therefore it could not be proven that the 
mutations were de novo. An analogous ACTB p.Ile75Thr mutation has been 
described5. Unfortunately, the patient was lost to follow-up, but was not thought to 
have comparable severe cerebral anomalies. In the same publication Poirier at al also 
reported a nine year old male with BWCFF and an ACTG1 mutation (p.Met153Ile), 
who had pachygyria. It should be noted that a case of agyria has also been 
documented with an ACTB mutation (p.Leu65Val)2,9. 
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Overall, it appears that ACTB mutations can be associated with a more severe 
craniofacial phenotype, whereas those in ACTG1 are more likely to result in 
significant brain structural abnormalities. However, given the small number of cases 
involved, it is not yet possible to definitively determine the differences in phenotype 
based on the gene affected. The phenotypic spectrum is likely to broaden with an 
increasing number of affected individuals being identified.  
 
Genetic and molecular basis 
 
Actin has six different protein isoforms: αskeletal-actin, αcardiac-actin, αsmooth-actin, and 
γsmooth-actin are expressed only in muscle cells. The cytoplasmic actin genes, ACTB 
(βcyto-actin) and ACTG1 (γcyto-actin), however, are ubiquitously expressed in 
vertebrates. These two isoforms share an almost identical structure, differing by only 
four amino acids16. Actins polymerise in vivo (F-actins), and these polymers play a 
number of crucial roles in the cellular cytoskeleton, for example maintenance of cell 
shape and mediation of cell-cell signalling. The ability of actin to rapidly polymerise 
and depolymerise allows for an adaptable and constantly changing cytoskeletal 
structure to regulate the intracellular environment and interactions with other cells18. 
There is some redundancy between cyto-actin isoforms, which may be expected, 
given the similarity of protein sequence, and they can easily co-polymerise19. For 
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example, Actg1-null mice fibroblasts show no reduction in overall actin levels due to 
increased levels of other isoforms, including βcyto-actin20.  
 
However, βcyto-actin and γcyto-actin have differential intracellular localisation 
patterns21, as well as being highly conserved across mammal and bird species, 
suggesting non-redundant roles. Actb-null mice do not survive to birth22. Loss of 
Actb exclusively in neurons results in abnormal cortical folding in the cerebellum 
and hippocampus, as well as partial agenesis of the corpus callosum23. Expression of 
Actb can also vary in a tissue-specific manner, i.e. miRNA-mediated regulation of 
translation via an alternative transcript affecting the 3’ UTR increases expression in 
neuronal cells24. In addition, post-translational modification by arginylation of βcyto-
actin aids cellular movement and increases actin polymerisation26. 
 
Actg1-null mice, in contrast, are viable, albeit with reduced survival in the 
immediate post-natal period26. Specific knockout of Actg1 in skeletal muscle results 
in progressive myopathy and muscle cell death in mice27. Actg1 regulation also 
differs: arginylated  γcyto-actin is marked for ubiquitin-mediated degradation28. 
Adjustment of Actg1 levels can additionally be achieved by nonsense-mediated 
decay through production of an alternative transcript including a premature 
termination codon29.  
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There is some evidence of tissue-specific cyto-actin functions, with relevance to the 
pathogenesis of BWCFF. Actin polymers play an important role in brain 
development. The actin cytoskeleton contributes to axonal growth via myosin 
interactions. It also acts as a guidance mechanism for the developing axon mediated 
by actin-binding proteins responding to chemical cues in the external environment30.  
As well as cytoplasmic functions, actin can regulate gene expression in neurons, 
controlling neurite outgrowth31. This appears to be mediated through the serum 
response factor (SRF) pathway.  
 
In auditory development, cyto-actin is required for stereocilia hair cell development 
in the ear in mice, but only one isoform needs to be present. However, loss of either 
Actb or Actg1 results in distinct types of progressive hearing loss over time32. Of note, 
familial sensorineural hearing loss with no other systemic features has been 
associated with mutations in ACTG1 (DFNA 20/26- MIM #604717). These are 
missense mutations, but are non-overlapping with those found in BWCFF33-34. 
Recurrent somatic mutations in ACTB have been found in large B-cell lymphoma35, 
and a somatic mutation has been shown in a gastric adenocarcinoma36. γcyto-actin is 
upregulated in sporadic lung and colon carcinomas, with an associated increase in 
invasiveness of the cancer cells37. Actin polymers (F-actin) can increase the 
transcriptional activity of the transcriptional co-activator β-catenin, known to be 
dysregulated in many cancers38.  
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Diagnosis and counselling 
 
A diagnosis of Baraitser-Winter syndrome should be considered in patients 
presenting with characteristic dysmorphism (metopic ridging/trigonocephaly, 
arched eyebrows, hypertelorism, congenital ptosis, short nose) together with 
intellectual disability of varying severity. Other suggestive findings include ocular 
coloboma and pachygyria. The age of presentation needs to be taken into account, as 
facial appearance changes significantly over time.  
 
Differential diagnoses may include Noonan syndrome [MIM # 163950], which shares 
some facial similarities, as well as pectus abnormalities and neck webbing. 
Coloboma is very rare in Noonan syndrome and it is not normally associated with 
cortical brain malformations.  The long palpebral fissures may be reminiscent of 
Kabuki syndrome [MIM #147920; MIM #300867]. Similarities may be found with 
other syndromes associated with hypertelorism (Teebi hypertelorism syndrome 
[MIM #145420], Aarskog syndrome [MIM #305400]) and at the extreme end, 
conditions with frontonasal dysplasia. Ptosis and pterygia overlap with features seen 
in Escobar syndrome [MIM #265000]. 
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Molecular diagnosis is made by sequencing of the ACTB and/or ACTG1 genes. This 
may be a single gene approach, or as part of NGS based targeted or whole exome 
sequencing. Mutations are usually de novo, however, in this review we report for 
the first time a parent with BWCFF and an affected child (Fig 1a, Patient 1, and 2a 
and 2b; detailed clinical data will be presented elsewhere).  
 
Several patients with a presentation suggestive for BWCFF syndrome with no 
ACTB/ACTG1 variants have been identified5, therefore there may be further 
molecular heterogeneity.    
 
As BWCFF is usually associated with de novo mutations, the recurrence risk for 
siblings is low. Prenatal testing can be offered for known variants.  
 
Investigations, management and surveillance 
 
Suggested investigations in a patient with probable or definite BWCFF should 
include: formal ophthalmological examination, audiometry, echocardiogram, and 
renal ultrasound scanning. Brain MRI should be considered in the presence of 
moderate to severe intellectual disability and/or seizure disorder. In patients with 
mild intellectual disability and without epilepsy, cerebral neuroimaging can be 
considered on a case by case basis. In cases of significant trigonocephaly, 
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hypertelorism, or premature fusion of other cranial sutures, referral to a craniofacial 
surgery department is indicated.    
 
Surveillance of psychomotor development and cognitive function will be required in 
all patients. The possible occurrence of a hearing impairment and its progression 
will need to be monitored.  Some patients will need surgical correction of their 
ptosis, and those with coloboma or microphthalmia will need screening for 
glaucoma as this can be a long term complication39. Treatment may be required for 
congenital cardiac disease, renal tract malformations and epilepsy. Cleft lip and 
palate will require surgical repair.  
 
So far, the occurrence of malignancy in BWCFF appears to be rare, and it is yet to be 
determined whether this condition is associated with a predisposition to cancer. 
Therefore, screening is currently not recommended.  
 
Conclusion 
 
BWCFF is becoming a defined clinical entity, however with a wider spectrum of 
severity than previously thought, with milder and more severe phenotypes having 
being identified. Typical craniofacial features are crucial in diagnosis, whereas 
pachygyria/lissencephaly and colobomata are important, but not consistent, clues 
(Table 1). There are also a number of features unique to individual patients, and it 
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remains to be determined whether these form part of the syndrome. Future 
challenges lie in understanding the functional consequences of the underlying actin 
mutations and the resulting phenotype. Given the ubiquitous expression of 
cytoplasmic actins, this will be a complex task.  
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Figure legends 
 
 
 
Figure 1a. BWCFF mother (2a&b; ages 3.5y and 31y)-daughter (1; age 6.75y) pair. 
Features common to both include arched eyebrows, bilateral colobomata, short nose 
with broad root, long philtrum and thin upper lip. Patient 1 has metopic ridging. 
Patient 2 had sagittal craniosynostosis, which has not been previously reported. Note 
coarsening of facial features with age in patient 2. The familial novel ACTB mutation 
is shown.  
Figure 1b. Three further BWCFF patients. Note typical facial appearance including 
arched eyebrows, ptosis (patients 3 & 5), hypertelorism, short nose, long philtrum and 
thin upper lip. Patient 4 (8y) has left sided unilateral, congenital glaucoma, not 
previously reported in BWCFF. Each patient’s mutation is shown. The mutation in 
patient 3 (8y) has been identified in one other patient40. Patient 4 has a novel 
mutation. The mutation in patient 5 (13y) is the most common in BWCFF (this patient 
was previously published5).  
Figure 2. Neuroimaging features: A & B axial T2 weighted images, C axial and D 
saggital T1 weighted images. Frontal pachygyria shown in A & B (black arrows) 
and more widespread pachygyria (black arrows) in C.  Short thick corpus 
callosum shown in D. Prominent perivascular spaces are shown in A & B. 
 
Figure 3. Recurrent mutations in BWCFF. ACTB (Refseq accession NM_001101.3) 
and ACTG1 (Refseq accession NM_001199954.1) genes are combined due to 
almost identical exon structure. Light grey: coding exons; dark grey: non coding 
exons. The first amino acid of each exon is shown. Functional domains: Divalent 
cation (Mg2+/Ca2+) binding domains (black arrows); Adenosine nucleotide 
binding domains (white arrows) and DNAse binding loop (triangles).  
Mutations with two or more documented cases are shown.
Table 1. Clinical features of BWCFF. Characteristics are divided 
according to frequency. Cardinal features of BWCFF highlighted in bold. 
Features with less than 10% occurrence in published literature not 
included.  
*Pachygyria/lissencephaly (60-70% of patients) and colobomata (25-30%) 
are major clues to the diagnosis of BWCFF.  This article is protected by copyright. All rights reserved.
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Figure 1 - legend as per manuscript text  
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